NCT07630402 Optimization of Cardiac Imaging in Women With Early-Stage Breast Cancer
| NCT ID | NCT07630402 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rochester |
| Condition | Breast Cancer With Low to Intermediate HER2 Expression |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-11-17 |
| Primary Completion | 2031-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-11-17 with a primary completion date of 2031-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine whether a personalized, risk-stratified surveillance strategy can safely reduce unnecessary cardiac imaging while preserving early detection of treatment-related cardiotoxicity in women with breast cancer (BC) receiving HER2-targeted therapy (HER2-TT).
Eligibility Criteria
Inclusion Criteria: * Female sex, age 18-79 years. * Histologically confirmed HER2-positive BC scheduled for ≈12 months of adjuvant HER2-TT * Baseline LVEF ≥ 55 % by 2-D echocardiography. * Ability to provide informed consent. Exclusion Criteria: * Prior HF, myocardial infarction, or cardiomyopathy. * Atrial fibrillation or significant valvular heart disease. * Cumulative anthracycline dose ≥ 250 mg/m². * Pregnancy or lactation. * Inability to comply with study procedures.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07630402 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 79 Years, studying Breast Cancer With Low to Intermediate HER2 Expression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07630402 currently recruiting?
Yes, NCT07630402 is actively recruiting participants. Contact the research team at kaily_laforce@urmc.rochester.edu for enrollment information.
Where is the NCT07630402 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT07630402 clinical trial?
NCT07630402 is sponsored by University of Rochester. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.